Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61N-005/10
A61K-035/74
A61K-038/19
A61K-039/00
출원번호
US-0669629
(2015-03-26)
등록번호
US-10016617
(2018-07-10)
발명자
/ 주소
Mason, Nicola
Paterson, Yvonne
출원인 / 주소
The Trustees of the University of Pennsylvania
대리인 / 주소
Cohen, Mark S.
인용정보
피인용 횟수 :
1인용 특허 :
74
초록
This invention provides methods for inducing an immune response against a Her-2/neu antigen-expressing tumor and for treating the same and vaccinating against the same in human and canine subjects using a combination of radiation therapy and a recombinant attenuated Listeria strain vaccine.
대표청구항▼
1. A method of treating a Her-2/neu-expressing tumor growth or cancer in a subject comprising the step of administering a combination of radiation therapy and a recombinant attenuated Listeria strain comprising a nucleic acid comprising a first open reading frame encoding a fusion polypeptide compri
1. A method of treating a Her-2/neu-expressing tumor growth or cancer in a subject comprising the step of administering a combination of radiation therapy and a recombinant attenuated Listeria strain comprising a nucleic acid comprising a first open reading frame encoding a fusion polypeptide comprising a Her-2/neu chimeric antigen fused to an additional polypeptide, said Her-2/neu chimeric antigen comprises amino acids as set forth in SEQ ID NO: 2, and a second open reading frame encoding a metabolic enzyme, wherein said metabolic enzyme complements an endogenous gene that is mutated in the chromosome of said recombinant attenuated Listeria strain, and wherein the administration of said radiation therapy comprises at least two administrations of said radiation therapy. 2. The method of claim 1, wherein said subject is a human adult or child. 3. The method of claim 1, wherein said subject is a canine. 4. The method of claim 1, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the mapped human MHC-class I epitopes. 5. The method of claim 1, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the canine MHC-class I epitopes. 6. The method of claim 1, wherein said nucleic acid molecule is integrated into the Listeria genome. 7. The method of claim 1, wherein said nucleic acid molecule is in a plasmid in said recombinant attenuated Listeria strain and wherein said plasmid is stably maintained in said recombinant attenuated Listeria strain in the absence of antibiotic selection. 8. The method of claim 1, wherein said recombinant Listeria comprises a deletion in the actA virulence gene. 9. The method of claim 1, wherein said additional polypeptide is selected from the group consisting of: a) non-hemolytic LLO protein or N-terminal fragment, b) a PEST sequence, or c) an ActA fragment. 10. The method of claim 1, wherein said metabolic enzyme encoded by said second open reading frame is an alanine racemase enzyme or a D-amino acid transferaseenzyme. 11. The method of claim 1, wherein said recombinant attenuated Listeria strain is ADXS31-164. 12. The method of claim 1, wherein said recombinant attenuated Listeria strain is administered with an independent adjuvant, wherein said adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSP) protein, a nucleotide molecule encoding a GM-CSP protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide. 13. The method of claim 1, wherein said radiation therapy is administered prior to administration of said recombinant attenuated Listeria strain. 14. The method of claim 1, wherein said cancer is osteosarcoma. 15. A method of eliciting an enhanced immune response against a Her-2/neu-expressing tumor growth or cancer in a subject comprising the step of administering a combination of radiation therapy and a recombinant attenuated Listeria strain comprising a nucleic acid comprising a first open reading frame encoding a fusion polypeptide comprising a Her-2/neu chimeric antigen fused to an additional polypeptide, said Her-2/neu chimeric antigen comprises amino acids as set forth in SEQ ID NO: 2, and a second open reading frame encoding a metabolic enzyme, wherein said metabolic enzyme complements an endogenous gene that is mutated in the chromosome of said recombinant attenuated Listeria strain, and wherein the administration of said radiation therapy comprises at least two administrations of said radiation therapy. 16. The method of claim 15, wherein said subject is a human adult or child. 17. The method of claim 15, wherein said subject is a canine. 18. The method of claim 15, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the mapped human MHC-class I epitopes. 19. The method of claim 15, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the canine MHC-class I epitopes. 20. The method of claim 15, wherein said nucleic acid molecule is integrated into the Listeria genome. 21. The method of claim 15, wherein said nucleic acid molecule is in a plasmid in said recombinant attenuated Listeria strain and wherein said plasmid is stably maintained in said recombinant attenuated Listeria strain in the absence of antibiotic selection. 22. The method of claim 15, wherein said recombinant Listeria comprises a deletion in the actA virulence gene. 23. The method of claim 15, wherein said additional polypeptide is selected from the group consisting of: a) non-hemolytic LLO protein or N-terminal fragment, b) a PEST sequence, or c) an ActA fragment. 24. The method of claim 15, wherein said metabolic enzyme encoded by said second open reading frame is an alanine racemase enzyme or a D-amino acid transferase enzyme. 25. The method of claim 15, wherein said recombinant attenuated Listeria strain is ADXS31-164. 26. The method of claim 15, wherein said recombinant attenuated Listeria strain is administered with an independent adjuvant, wherein said adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSP) protein, a nucleotide molecule encoding a GM-CSP protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide. 27. The method of claim 15, wherein said radiation therapy is administered prior to administration of said recombinant attenuated Listeria strain. 28. The method of claim 15, wherein said cancer is osteosarcoma. 29. The method of claim 15, wherein said tumor growth or cancer is a relapse or metastasis. 30. The method of claim 29, wherein said metastasis is pulmonary metastatic disease. 31. The method of claim 15, wherein said eliciting an enhanced immune response results in an increased Her-2/neu specific T cell response. 32. A method of prolonging survival in a subject suffering from a Her-2/neu-expressing tumor growth or cancer comprising the step of administering a combination of radiation therapy and a recombinant attenuated Listeria strain comprising a nucleic acid comprising a first open reading frame encoding a fusion polypeptide comprising a Her-2/neu chimeric antigen fused to an additional polypeptide, said Her-2/neu chimeric antigen comprises amino acids as set forth in SEQ ID NO: 2, and a second open reading frame encoding a metabolic enzyme, wherein said metabolic enzyme complements an endogenous gene that is mutated in the chromosome of said recombinant attenuated Listeria strain, and wherein the administration of said radiation therapy comprises at least two administrations of said radiation therapy. 33. The method of claim 32, wherein said subject is a human adult or child. 34. The method of claim 32, wherein said subject is a canine. 35. The method of claim 32, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the mapped human MHC-class I epitopes. 36. The method of claim 32, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the canine MHC-class I epitopes. 37. The method of claim 32, wherein said nucleic acid molecule is integrated into the Listeria genome. 38. The method of claim 32, wherein said nucleic acid molecule is in a plasmid in said recombinant attenuated Listeria strain and wherein said plasmid is stably maintained in said recombinant attenuated Listeria strain in the absence of antibiotic selection. 39. The method of claim 32, wherein said recombinant Listeria comprises a deletion in the actA virulence gene. 40. The method of claim 32, wherein said additional polypeptide is selected from the group consisting of: a) non-hemolytic LLO protein or N-terminal fragment, b) a PEST sequence, or c) an ActA fragment. 41. The method of claim 32, wherein said metabolic enzyme encoded by said second open reading frame is an alanine racemase enzyme or a D-amino acid transferase enzyme. 42. The method of claim 32, wherein said recombinant attenuated Listeria strain is ADXS31-164. 43. The method of claim 32, wherein said recombinant attenuated Listeria strain is administered with an independent adjuvant, wherein said adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSP) protein, a nucleotide molecule encoding a GM-CSP protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide. 44. The method of claim 32, wherein said radiation therapy is administered prior to administration of said recombinant attenuated Listeria strain. 45. The method of claim 32, wherein said cancer is osteosarcoma. 46. The method of claim 32, wherein said tumor growth or cancer is a relapse or metastasis. 47. The method of claim 46, wherein said metastasis is pulmonary metastatic disease. 48. A method of delaying metastatic disease in a subject suffering from a Her-2/neu-expressing tumor growth or cancer comprising the step of administering a combination of radiation therapy and a recombinant attenuated Listeria strain comprising a nucleic acid comprising a first open reading frame encoding a fusion polypeptide comprising a Her-2/neu chimeric antigen fused to an additional polypeptide, said Her-2/neu chimeric antigen comprises amino acids as set forth in SEQ ID NO: 2, and a second open reading frame encoding a metabolic enzyme, wherein said metabolic enzyme complements an endogenous gene that is mutated in the chromosome of said recombinant attenuated Listeria strain, and wherein the administration of said radiation therapy comprises at least two administrations of said radiation therapy. 49. The method of claim 48, wherein said subject is a human adult or child. 50. The method of claim 48, wherein said subject is a canine. 51. The method of claim 48, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the mapped human MHC-class I epitopes. 52. The method of claim 1, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the canine MHC-class I epitopes. 53. The method of claim 48, wherein said nucleic acid molecule is integrated into the Listeria genome. 54. The method of claim 48, wherein said nucleic acid molecule is in a plasmid in said recombinant attenuated Listeria strain and wherein said plasmid is stably maintained in said recombinant attenuated Listeria strain in the absence of antibiotic selection. 55. The method of claim 48, wherein said recombinant Listeria comprises a deletion in the actA virulence gene. 56. The method of claim 48, wherein said additional polypeptide is selected from the group consisting of: a) non-hemolytic LLO protein or N-terminal fragment, b) a PEST sequence, or c) an ActA fragment. 57. The method of claim 48, wherein said metabolic enzyme encoded by said second open reading frame is an alanine racemase enzyme or a D-amino acid transferaseenzyme. 58. The method of claim 48, wherein said recombinant attenuated Listeria strain is ADXS31-164. 59. The method of claim 48, wherein said recombinant attenuated Listeria strain is administered with an independent adjuvant, wherein said adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSP) protein, a nucleotide molecule encoding a GM-CSP protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide. 60. The method of claim 48, wherein said radiation therapy is administered prior to administration of said recombinant attenuated Listeria strain. 61. The method of claim 48, wherein said cancer is osteosarcoma. 62. The method of claim 48, wherein said tumor growth or cancer is a relapse or metastasis. 63. The method of claim 62, wherein said metastasis is pulmonary metastatic disease. 64. A method of breaking tolerance to Her-2/neu in a subject suffering from a Her-2/neu-expressing tumor growth or cancer comprising the step of administering a combination of radiation therapy and a recombinant attenuated Listeria strain comprising a nucleic acid comprising a first open reading frame encoding a fusion polypeptide comprising a Her-2/neu chimeric antigen fused to an additional adjuvant, said Her-2/neu chimeric antigen comprises amino acids as set forth in SEQ ID NO: 2, and a second open reading frame encoding a metabolic enzyme, wherein said metabolic enzyme complements an endogenous gene that is mutated in the chromosome of said recombinant attenuated Listeria strain, and wherein the administration of said radiation therapy comprises at least two administrations of said radiation therapy. 65. The method of claim 64, wherein said subject is a human adult or child. 66. The method of claim 64, wherein said subject is a canine. 67. The method of claim 64, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the mapped human MHC-class I epitopes. 68. The method of claim 64, wherein said Her-2/neu chimeric antigen comprises at least 5, 9, 13, 14, or 17 of the canine MHC-class I epitopes. 69. The method of claim 64, wherein said nucleic acid molecule is integrated into the Listeria genome. 70. The method of claim 64, wherein said nucleic acid molecule is in a plasmid in said recombinant attenuated Listeria strain and wherein said plasmid is stably maintained in said recombinant attenuated Listeria strain in the absence of antibiotic selection. 71. The method of claim 64, wherein said recombinant Listeria comprises a deletion in the actA virulence gene. 72. The method of claim 64, wherein said additional polypeptide is selected from the group consisting of: a) non-hemolytic LLO protein or N-terminal fragment, b) a PEST sequence, or c) an ActA fragment. 73. The method of claim 64, wherein said metabolic enzyme encoded by said second open reading frame is an alanine racemase enzyme or a D-amino acid transferaseenzyme. 74. The method of claim 64, wherein said recombinant attenuated Listeria strain is ADXS31-164. 75. The method of claim 64, wherein said recombinant attenuated Listeria strain is administered with an independent adjuvant, wherein said adjuvant comprises a granulocyte/macrophage colony-stimulating factor (GM-CSP) protein, a nucleotide molecule encoding a GM-CSP protein, saponin QS21, monophosphoryl lipid A, or an unmethylated CpG-containing oligonucleotide. 76. The method of claim 64, wherein said radiation therapy is administered prior to administration of said recombinant attenuated Listeria strain. 77. The method of claim 64, wherein said cancer is osteosarcoma. 78. The method of claim 64, wherein said tumor growth or cancer is a relapse or metastasis. 79. The method of claim 78, wherein said metastasis is pulmonary metastatic disease. 80. The method of claim 1, wherein said tumor growth or cancer is a relapse or metastasis. 81. The method of claim 80, wherein said metastasis is pulmonary metastatic disease.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (74)
Singh, Reshma; Paterson, Yvonne, -based and LLO-based vaccines.
Paterson, Yvonne; Souders, Nicholas; Sewell, Duane; Pan, Zhen-kun; Singh, Reshma, Compositions and methods for enhancing the immunogenicity of antigens.
Shahabi, Vafa; Wallecha, Anu; Maciag, Paulo C.; Paterson, Yvonne; Mason, Nicola; Seavey, Matthew, Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Kessick Michael A. (Edmonton CAX) George Zacharia M. (Edmonton CAX) Schneider Linda G. (Edmonton CAX), Formation of coke from heavy crude oils in the presence of calcium carbonate.
Korman, Alan J.; Srinivasan, Mohan; Wang, Changyu; Selby, Mark J.; Chen, Bingliana; Cardarelli, Josephine M., Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics.
Karp, Nelson M., Immunizing compositions comprising recombinant attenuated self-replicating viral RNA replicons encoding an epitope obtained from the HIV-1 matrix protein myrstate binding site.
Frankel Fred R. ; Portnoy Daniel A., Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use.
Yang Yan-ping (Willowdale CAX) Kandil Ali (Willowdale CAX) Gisonni Lucy (Toronto CAX) Fahim Raafat Emil Fahmy (Mississauga CAX) Klein Michel Henri (Willowdale CAX), Immunogenic conjugate molecules.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Mann Michael J. ; Diet Frank P.,DEX ; Dzau Victor J. ; Gibbons Gary H. ; Von Der Leyen Heiko,DEX, Intracellular delivery of nucleic acids using pressure.
Lurquin Christophe,BEX ; Brasseur Francis,BEX ; Boon-Falleur Thierry,BEX, Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof.
Dubensky, Jr., Thomas W.; Brockstedt, Dirk G.; Cook, David N., Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof.
Sanford John C. (Geneva) DeVit Michael J. (Geneva NY) Bruner Ronald F. (Sewell NJ) Johnston Stephen A. (Durham NC), Method and apparatus for introducing biological substances into living cells.
Powell Robert J. ; Lewis George K. ; Hone David M., Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same.
Carson Dennis A. (Del Mar CA) Raz Eyal (San Diego CA), Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleoti.
Carson Dennis A. ; Raz Eyal ; Howell Meredith L., Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptide.
Frankel,Fred R.; Portnoy,Daniel A., Methods of inducing immune responses through the administration of auxtrophic attenuated dal/dat double mutant Listeria strains.
Boon Thierry (Brussels BEX) van der Bruggen Pierre (Brussels BEX) Van den Eynde Benoit (Brussels BEX) Van Pel Aline (Brussels BEX) De Plaen Etienne (Brussels BEX) Lurquin Christophe (Brussels BEX) Ch, Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Dubensky, Jr., Thomas W.; Portnoy, Daniel A.; Luckett, Jr., William S.; Cook, David N., Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof.
Brown Joseph P. (Seattle WA) Estin Charles D. (Bainbridge Island WA) Plowman Gregory D. (Seattle WA) Rose Timothy M. (Seattle WA) Hellstrom Karl E. (Seattle WA) Hellstrom Ingegerd (Seattle WA) Purchi, Recombinant viruses encoding the human melanoma-associated antigen.
Harn, Jr., Donald A.; Paterson, Yvonne; McEwen, Lisa, Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals.
Dubensky, Jr., Thomas W.; Brockstedt, Dirk G.; Cook, David N., attenuated for entry into non-phagocytic cells, vaccines comprising the , and methods of use thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.